17.0% of FHLC Holdings Experiencing Recent Insider Purchases
Insider Buying Activity: 17.0% of the weighted holdings in the Fidelity MSCI Health Care Index ETF (FHLC) have seen insider buying in the past six months.
Avantor Inc (AVTR): This company, making up 0.12% of FHLC, has had two directors and officers purchase shares recently, with the ETF holding $3,215,377 worth of AVTR.
Establishment Labs Holdings Inc (ESTA): Representing approximately 0.02% of FHLC, ESTA has also seen insider purchases from two directors and officers, with the ETF holding $490,723 worth of ESTA.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Analyst Views on ESTA
About ESTA
About the author


Stock Sale Announcement: Establishment Labs' Director Juan Jose Chacon Quiros plans to sell 330,000 shares of its common stock.
Market Value: The total market value of the shares being sold is approximately $20.67 million.
- Share Increase: Rice Hall James & Associates acquired 574,877 shares of QuidelOrtho in Q4 2026, reflecting confidence in the company's future prospects despite a 43.4% decline in stock price over the past year.
- Investment Value: This acquisition raised QuidelOrtho's stake to 1.3% of the fund's 13F reportable assets, indicating recognition of its potential value, which may attract further investor interest.
- Market Performance: As of February 13, 2026, QuidelOrtho's market capitalization stood at $1.6 billion with a current price of $23.58, trailing the S&P 500 by 55.2 percentage points, highlighting competitive pressures in the market.
- Strategic Adjustments: QuidelOrtho is undergoing strategic adjustments, including strengthening its product pipeline and improving spending returns, with analysts expecting these efforts to yield modest revenue and operating profit growth in the coming years.
- Increased Holdings: Rice Hall James purchased 574,877 shares of QuidelOrtho in Q4, raising its total stake to 833,791 shares valued at $23.8 million, reflecting a positive outlook on the company's future prospects.
- Investment Value Growth: The position's value increased by $16.2 million at quarter-end, indicating a rise in stock price and additional share purchases, suggesting the fund's optimistic view on QuidelOrtho's potential value.
- Industry Position: As a leader in in vitro diagnostics, QuidelOrtho has struggled with consistent revenue growth and profitability in recent years, but its strategic adjustments and strengthened product pipeline may improve financial performance, attracting value investors.
- Market Expectations: Analysts expect QuidelOrtho to achieve modest revenue and operating profit growth in the coming years, although the Motley Fool analyst team did not include it in their list of top investment stocks, indicating a divergence in market perceptions of its potential.
- Share Increase: Rice Hall James & Associates, LLC increased its stake in Stride by 122,430 shares in Q4 2026, bringing its ownership to 1.5%, indicating confidence in Stride's future growth potential.
- Market Value Fluctuation: Despite the increase, Stride's quarter-end market value fell by $17.7 million, reflecting the impact of stock price movements and additional shares, suggesting market concerns about its short-term performance.
- Earnings Outlook: During Stride's Q4 earnings call, management reaffirmed full-year revenue guidance while raising adjusted operating income expectations, indicating that the market's negative reaction may have been overstated, presenting a potential undervaluation opportunity.
- Market Performance: Stride's stock price has dropped 39.5% over the past year and underperformed the S&P 500 by 51.2 percentage points, highlighting challenges in the education market but also providing potential buying opportunities for investors.
- Significant Revenue Growth: Establishment Labs reported fourth-quarter revenue of $64.6 million for 2025, representing a 45.2% year-over-year increase, with U.S. Motiva sales contributing $17.3 million, highlighting the company's strong market performance and growth potential.
- Gross Margin Improvement: The gross margin exceeded 70% for the second consecutive quarter, reaching 70.5%, up from 68.5% last year, reflecting successful cost management and operational efficiency, with expectations for further margin enhancement in the future.
- Rapid Market Share Expansion: The company achieved approximately 20% augmentation market share in the U.S. within a single year, indicating that product innovation and strong demand have significantly driven sales growth.
- Optimistic 2026 Outlook: Management provided guidance for 2026 revenue of $264 million to $266 million, representing a growth rate of 25% to 26%, and plans to expand the U.S. sales force to further enhance market penetration and product adoption.
- Earnings Highlights: Establishment Labs reported a Q4 GAAP EPS of -$0.09, beating expectations by $0.13, indicating a trend towards improved profitability for the company.
- Revenue Growth: Q4 revenue reached $64.62M, a 45.2% year-over-year increase, exceeding market expectations by $0.5M and reflecting strong performance amid robust market demand.
- Future Guidance: The company projects 2026 revenue between $264M and $266M, representing a 25.1% to 26.0% increase over 2025, showcasing sustained growth potential and market confidence.
- Long-term Growth Outlook: Revenue for 2027 is expected to grow by at least 25%, indicating the company's commitment to expanding market share and enhancing profitability in the coming years.








